Check Out Our Latest Analysis on SYRESpyre Therapeutics Stock Down 2.9%Shares of NASDAQ:SYRE opened at $15.98 on Tuesday. Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. On average, analysts expect that Spyre Therapeutics will post -4.46 earnings per share for the current year. Spyre Therapeutics Company Profile(Get Free Report)Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). Featured StoriesReceive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.